Simtriyo (centanafadine)
Otsuka Pharmaceutical
ApprovedJul 24, 2026
Marketer take
A new ADHD medicine entering a large, heavily generic market, so psychiatrists, pediatricians and primary care will need clear positioning against stimulants and existing non-stimulants, and payer step edits will be a hurdle.
- Sponsor company
- Otsuka Pharmaceutical
- Indication
- To treat attention-deficit hyperactivity disorder
- Therapeutic area
- Psychiatry
- Event
- FDA approval
- Date
- Jul 24, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?